Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00492570
Status:
COMPLETED
Last Update Posted:
2009-06-16
First Post:
2007-06-25
Brief Title:
GER-009-06-AVX Early Therapy in Multiple Sclerosis
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
GER-009-06-AVX Early Therapy in Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FIT
Brief Summary:
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis MS and the cognitive dysfunction that accompanies MS and to record safety data for Avonex
Detailed Description:
This study will address the cognitive dysfunction associated with MS It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients Safety data will also be collected during this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None